The peptide & supplement tracking library

Retatrutide is an experimental once-weekly injectable being studied for obesity and type 2 diabetes. It is the first triple agonist (acting on GLP-1, GIP, and glucagon receptors) to reach Phase 3. Because it is investigational, it is only legitimately available through clinical trials — products sold elsewhere are unregulated and of unknown identity, purity, and dose.

Tirzepatide is a prescription once-weekly injectable that activates two incretin receptors (GIP and GLP-1). It is approved and clinician-managed. People using it commonly track appetite, food tolerance, protein intake, and weight, because appetite and gastric emptying are strongly affected.

Semaglutide is a prescription GLP-1 receptor agonist, injectable weekly (Ozempic/Wegovy) or oral daily (Rybelsus). It is approved and clinician-managed. Appetite reduction is prominent, so protein intake and hydration are commonly tracked.

CJC-1295 is a synthetic analog of growth-hormone-releasing hormone (GHRH) discussed in recovery, sleep, and body-composition contexts, frequently paired with ipamorelin. It is not an approved medication; human evidence is limited.

Ipamorelin is a selective growth-hormone secretagogue often discussed alongside CJC-1295. It is not approved; human data are limited.

Tesamorelin (Egrifta) is the only FDA-approved GHRH analog, approved specifically for HIV-associated lipodystrophy. It is sometimes discussed more broadly for visceral fat; that broader use is off-label and a clinician-level decision.

Sermorelin is a GHRH analog historically used to assess growth-hormone deficiency and now common in wellness/longevity clinics via compounding. It is usually framed as a gentler secretagogue; it is still clinician-territory.

AOD-9604 is a fragment of the growth-hormone molecule marketed in fat-loss contexts. It is not approved, and clinical fat-loss evidence in humans is weak. Worth a frank clinician conversation about whether it adds anything over fundamentals.

MOTS-c is a mitochondrial-derived peptide studied in metabolism and exercise-physiology research. Human clinical evidence is early; it is not an approved medication.

BPC-157 is a synthetic peptide widely discussed for soft-tissue and gut recovery. It has not been approved for human use and lacks completed human clinical trials. Anyone considering it should discuss legality, sourcing, and safety directly with a clinician.

TB-500 is a peptide fragment discussed in injury-recovery communities, often alongside BPC-157. It is not approved for human use and human data are sparse. Clinician guidance is essential.

The GLOW Stack commonly refers to a vendor or community combination of GHK-Cu, BPC-157, and TB-500. It is discussed around skin appearance, soft-tissue recovery, and general repair signaling, but it is not a validated or standardized treatment plan.

KLOW Stack commonly refers informally to GHK-Cu, BPC-157, TB-500, and KPV. Vendor and community formulations can differ, no fixed ratio is authoritative, and evidence for the combined formulation is limited.

The Wolverine Stack commonly refers to the pairing of BPC-157 and TB-500 in injury-recovery communities. The name is popular, but neither compound is FDA-approved for human use and human evidence remains limited.

This combination is discussed at the intersection of GLP/GIP/glucagon research and growth-hormone-axis therapy. It should be understood as an educational overview, not a protocol or recommendation.

This triple combination is discussed in body-composition communities, combining a metabolic investigational drug with GH-axis agents. The combination has no standardized clinical role in Reta's current data.

CJC-1295 plus ipamorelin is a widely discussed secretagogue pairing intended to stimulate the body's own growth-hormone pulses. Human evidence for wellness use is limited, and the combination requires clinician-level risk review.

People commonly discuss pairing GLP-1 or multi-incretin medications with GH-pathway agents for body composition, appetite, recovery, or visceral-fat goals. Reta presents this as an educational map, not a recommended protocol.

Myostatin inhibitors aim to reduce signaling that limits muscle growth. The category includes clinical-stage medicines for muscle-wasting disorders, older discontinued programs, animal research tools, and community-discussed research peptides.

GHK-Cu is a copper-binding peptide. In topical skincare it is mainstream and regulated as a cosmetic. Injectable use is a different, unapproved risk category and needs clinician oversight.

Melanotan II is an unapproved melanocortin-receptor agonist marketed for tanning and libido effects. It is unregulated, and there are documented safety concerns, including reports of new or changing moles/melanoma during or after use.

NAD+ is a coenzyme central to cellular energy metabolism. Oral precursors (NMN, NR) are supplements; IV/injectable NAD+ is a clinic-based wellness offering, not an approved therapy. Benefits in humans are still being studied.

Glutathione is the body's major intracellular antioxidant. Oral supplements exist; IV glutathione is marketed for skin and 'detox' but is not FDA-approved for those uses, and safety of unregulated IV products is a concern.

L-carnitine helps transport fatty acids into mitochondria for energy. Oral supplements are common; prescription injectable levocarnitine is approved only for carnitine deficiency. Fat-loss/performance injections are off-label with limited evidence.

Bremelanotide is a melanocortin-receptor agonist approved for a specific sexual-desire condition in premenopausal women and discussed more broadly for libido. Broader use is off-label and a clinician-level decision; unregulated products carry identity and purity risks.

Thymosin Alpha-1 is a naturally occurring peptide discussed in immune-modulation contexts. It is not FDA-approved in the US; human evidence for wellness use is limited, and any use should be clinician-directed.

Thymosin Beta-4 is a naturally occurring peptide discussed in tissue-repair contexts and closely related to the marketed TB-500 fragment. It is not approved for human use and human data are sparse — clinician guidance is essential.

SS-31 (elamipretide) is an investigational mitochondria-targeting peptide studied in specific disease trials. It is not an approved medication, and general wellness evidence is not established.

Epitalon is a synthetic peptide discussed in longevity and sleep/circadian contexts. It is not approved for human use, and robust human evidence is lacking — a frank clinician conversation is warranted.

DSIP is a naturally occurring peptide discussed in sleep and stress-response contexts. It is not approved for human use, and human data are limited — track sleep honestly and involve a clinician.

KPV is a short peptide discussed in inflammation and gut-comfort contexts. It is not approved for human use, and human evidence is limited — clinician guidance is essential.

LL-37 is a naturally occurring antimicrobial peptide studied in immune and wound-context research. It is not approved for human use, and supplemental-use evidence is limited — clinician guidance is essential.

Selank is a synthetic peptide discussed in anxiety and cognition contexts. It is not FDA-approved, and human evidence outside a small research base is limited — clinician guidance is essential.

Semax is a synthetic peptide discussed in cognition and focus contexts, commonly used intranasally. It is not FDA-approved, and human evidence outside a limited research base is small — clinician guidance is essential.

IGF-1 LR3 is a modified insulin-like growth factor discussed in muscle-growth contexts. It is not approved for human use and carries real safety concerns — this entry exists to inform, not to guide use.

Hexarelin is a growth-hormone secretagogue discussed alongside other GH peptides. It is not approved for human use; human data are limited and GH-axis effects warrant clinician oversight.

GHRP-2 is a growth-hormone-releasing peptide discussed for recovery and body composition, often alongside a GHRH analog. It is not approved for human use; human data are limited.

GHRP-6 is a growth-hormone-releasing peptide known for a strong hunger effect, discussed for recovery and body composition. It is not approved for human use; human data are limited.

Kisspeptin is a naturally occurring peptide central to reproductive-hormone signaling and studied in fertility research. It is not an approved medication; wellness-use evidence is not established.

Creatine monohydrate is among the most-studied supplements, commonly used to support strength, training output, and muscle over time. Inexpensive and well tolerated by most people; consistency matters more than timing.

A mineral many people under-consume. Glycinate is commonly chosen for evening use and sleep; citrate leans laxative. Often tracked alongside a wind-down routine.

EPA/DHA fatty acids commonly taken for cardiovascular and general health, and discussed for joint comfort and recovery. Quality varies between products.

Commonly supplemented, especially with limited sun exposure. One of the few supplements where a cheap blood test tells you exactly where you stand — worth testing rather than guessing.

A water-soluble vitamin commonly supplemented for general and immune health. Most people can meet needs from food; supplements are commonly tracked during winter or heavy training blocks.

B12 supports red blood cells and nerve function. Deficiency is most common with plant-based diets, older age, or acid-reducing medications — a blood test tells you where you stand.

A combination of B vitamins (B1, B2, B3, B5, B6, B7, B9, B12) involved in energy metabolism. Commonly tracked as a morning habit; bright-yellow urine afterward is normal (riboflavin).

A fat-soluble vitamin discussed for bone and cardiovascular health, and commonly paired with vitamin D3. Anyone on blood thinners needs a clinician conversation before touching vitamin K in any form.

An essential mineral involved in immune function, skin, and hormone metabolism. Commonly tracked seasonally or during heavy training. Long-term high doses deplete copper — dose matters.

An electrolyte most people under-consume relative to sodium. Food (fruit, vegetables, dairy) is the primary source; supplements are capped at small doses because too much potassium is genuinely dangerous, especially with kidney issues or certain medications.

Drink mixes combining sodium, potassium, and often magnesium. Commonly tracked alongside water targets — especially with heavy sweating, low-carb eating, or reduced appetite on GLP-class medications where fluid intake drops.

A convenient way to close the gap to a daily protein target — especially useful when appetite is suppressed and whole-food volume is hard. Whey, casein, and plant blends all work; total daily protein matters most.

Hydrolyzed collagen commonly tracked for joint comfort, skin, and connective-tissue support, often taken with vitamin C. Evidence is moderate for joint comfort and skin hydration; it is not a complete protein for muscle purposes.

Free-form amino acids marketed around training. If daily protein is already adequate, they add little — most useful for training fasted or when whole protein isn't practical. EAAs (all nine essentials) are generally preferred over BCAAs alone.

Multi-ingredient formulas usually built around caffeine, often with citrulline and beta-alanine. Effects and stimulant content vary enormously between products; the caffeine dose is the number to actually track.

A hormone your body already makes to signal darkness. Most useful for shifting sleep timing (jet lag, schedule changes); lower doses are commonly discussed as sufficient. It's a timing signal, not a sedative.

A simple amino acid discussed for sleep quality, often taken before bed. Small studies suggest improved subjective sleep; it's inexpensive, mildly sweet, and well tolerated.

An amino acid from tea discussed for calm focus without sedation. Commonly paired with caffeine during the day (smoothing jitters) or taken in the evening as part of a wind-down.

An adaptogenic herb discussed for stress, sleep, and recovery. Trials suggest modest reductions in perceived stress and cortisol. Rare liver-injury reports and thyroid interactions make it worth mentioning to your clinician, and many take breaks rather than running it year-round.

Live microorganisms taken for gut health. Evidence is strain- and situation-specific (e.g., around antibiotics); generic daily use has weaker support. Fermented foods are a reasonable alternative worth discussing.

A soluble fiber with solid evidence for regularity and LDL cholesterol support. Commonly tracked on GLP-class protocols where constipation and low food volume are common. Start low and drink plenty of water.

A plant alkaloid studied for blood sugar and lipids, with modest effects in trials. It meaningfully interacts with many medications (including diabetes drugs), so it belongs in a clinician conversation — especially if you're already on metabolic medication.

A cysteine source that supports glutathione, the body's main antioxidant. Discussed for respiratory health and antioxidant support. Wellness-use evidence is mixed — worth an honest trial with a defined outcome.

A compound central to mitochondrial energy production, most commonly discussed alongside statin therapy (statins lower CoQ10 levels) and for heart health. Ubiquinol is the better-absorbed form.